468 related articles for article (PubMed ID: 25057888)
1. The molecular regulation of Janus kinase (JAK) activation.
Babon JJ; Lucet IS; Murphy JM; Nicola NA; Varghese LN
Biochem J; 2014 Aug; 462(1):1-13. PubMed ID: 25057888
[TBL] [Abstract][Full Text] [Related]
2. Suppressor of Cytokine Signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1.
Linossi EM; Chandrashekaran IR; Kolesnik TB; Murphy JM; Webb AI; Willson TA; Kedzierski L; Bullock AN; Babon JJ; Norton RS; Nicola NA; Nicholson SE
PLoS One; 2013; 8(8):e70536. PubMed ID: 23990909
[TBL] [Abstract][Full Text] [Related]
3. Janus Kinase 3 (JAK3): A Critical Conserved Node in Immunity Disrupted in Immune Cell Cancer and Immunodeficiency.
Liongue C; Ratnayake T; Basheer F; Ward AC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474223
[TBL] [Abstract][Full Text] [Related]
4. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.
Oh ST; Simonds EF; Jones C; Hale MB; Goltsev Y; Gibbs KD; Merker JD; Zehnder JL; Nolan GP; Gotlib J
Blood; 2010 Aug; 116(6):988-92. PubMed ID: 20404132
[TBL] [Abstract][Full Text] [Related]
5. JAK: Not Just Another Kinase.
Agashe RP; Lippman SM; Kurzrock R
Mol Cancer Ther; 2022 Dec; 21(12):1757-1764. PubMed ID: 36252553
[TBL] [Abstract][Full Text] [Related]
6. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
[TBL] [Abstract][Full Text] [Related]
7. Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies.
Rodriguez Moncivais OJ; Chavez SA; Estrada Jimenez VH; Sun S; Li L; Kirken RA; Rodriguez G
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834019
[TBL] [Abstract][Full Text] [Related]
8. JAK1: Number one in the family; number one in inflammation?
Spinelli FR; Colbert RA; Gadina M
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii3-ii10. PubMed ID: 33950229
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells.
Bellucci R; Nguyen HN; Martin A; Heinrichs S; Schinzel AC; Hahn WC; Ritz J
J Clin Invest; 2012 Jul; 122(7):2369-83. PubMed ID: 22684105
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.
Varghese LN; Ungureanu D; Liau NP; Young SN; Laktyushin A; Hammaren H; Lucet IS; Nicola NA; Silvennoinen O; Babon JJ; Murphy JM
Biochem J; 2014 Mar; 458(2):395-405. PubMed ID: 24354892
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712.
Breinlinger E; Van Epps S; Friedman M; Argiriadi M; Chien E; Chhor G; Cowart M; Dunstan T; Graff C; Hardee D; Herold JM; Little A; McCarthy R; Parmentier J; Perham M; Qiu W; Schrimpf M; Vargo T; Webster MP; Wu F; Bennett D; Edmunds J
J Med Chem; 2023 Oct; 66(20):14335-14356. PubMed ID: 37823891
[TBL] [Abstract][Full Text] [Related]
12. JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia.
Degryse S; Cools J
J Hematol Oncol; 2015 Jul; 8():91. PubMed ID: 26208852
[TBL] [Abstract][Full Text] [Related]
13. Progress on the Pharmacological Targeting of Janus Pseudokinases.
Henry SP; Jorgensen WL
J Med Chem; 2023 Aug; 66(16):10959-10990. PubMed ID: 37578217
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling.
Abraham BG; Haikarainen T; Vuorio J; Girych M; Virtanen AT; Kurttila A; Karathanasis C; Heilemann M; Sharma V; Vattulainen I; Silvennoinen O
Sci Adv; 2024 Mar; 10(10):eadl2097. PubMed ID: 38457493
[TBL] [Abstract][Full Text] [Related]
15. JAK2 activation by growth hormone and other cytokines.
Waters MJ; Brooks AJ
Biochem J; 2015 Feb; 466(1):1-11. PubMed ID: 25656053
[TBL] [Abstract][Full Text] [Related]
16. Integration of fingerprint-based similarity searching and kernel-based partial least squares analysis to predict inhibitory activity against CSK, HER2, JAK1, JAK2, and JAK3.
Deokar H; Deokar M; Buolamwini JK
Mol Divers; 2024 Apr; 28(2):497-507. PubMed ID: 36648693
[TBL] [Abstract][Full Text] [Related]
17. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors.
Jensen LT; Attfield KE; Feldmann M; Fugger L
EBioMedicine; 2023 Nov; 97():104840. PubMed ID: 37863021
[TBL] [Abstract][Full Text] [Related]
18. Negative regulators of cytokine signal transduction.
Hilton DJ
Cell Mol Life Sci; 1999 Sep; 55(12):1568-77. PubMed ID: 10526574
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine.
Kavanagh ME; Horning BD; Khattri R; Roy N; Lu JP; Whitby LR; Ye E; Brannon JC; Parker A; Chick JM; Eissler CL; Wong AJ; Rodriguez JL; Rodiles S; Masuda K; Teijaro JR; Simon GM; Patricelli MP; Cravatt BF
Nat Chem Biol; 2022 Dec; 18(12):1388-1398. PubMed ID: 36097295
[TBL] [Abstract][Full Text] [Related]
20. Recent progress on tyrosine kinase 2 JH2 inhibitors.
Deng L; Wan L; Liao T; Wang L; Wang J; Wu X; Shi J
Int Immunopharmacol; 2023 Aug; 121():110434. PubMed ID: 37315371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
